Notícias

Moderna and Merck are surging today after the two companies said their experimental mRNA-based treatment succeeded in a late-stage study of high-risk melanoma patients. The SPDR S&P Biotech ETF (XBI) jumped nearly 5%, while the NYSE Arca Pharmaceutical Index climbed over 3%. A positive clinical-trial result typically moves the companies developing the drug—and perhaps their closest competitors—not the entire healthcare sector.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

Three Pfizer insiders executed transactions directly on the heels of the drugmaker’s second-quarter earnings report.

Millions of dollars are available to eligible Chantix buyers, but consumers have until September 14 to submit a claim.

Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call

SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.

This problem has a solution, and Pfizer is implementing it.

Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.

S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar

The stock's 6.4% yield is attractive, but it comes with risk.

Volatility in the stock market and the Magnificent Seven dominate the headlines. Investors are repositioning toward more value-based funds.

Novavax secures key partnerships and raises 2026 outlook while advancing its adjuvant platform in infectious disease and oncology.

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?

Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s chief executive, Pascal Soriot. After plunging on a Financial Times report of merger discussions with Bristol-Myers Squibb shares of AstraZeneca recovered somewhat when Reuters reported there are no ongoing talks. After rebuffing Pfizer’s $120 billion takeover bid in 2014, he steadily transformed AstraZeneca into one of the drug industry’s top growth stories.

Pfizer increased its savings target and revenue outlook, but investors remained focused on patent expirations and pipeline execution.

Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

Moby summary of Pfizer Inc.'s Q2 2026 earnings call

The quarter exposed where Pfizer's recovery is really coming from

Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

Rising sales of drugs for cancer and heart disease helped offset steep declines for Pfizer’s Covid-19 products.

Pfizer faces $17 billion patent cliff as investors brace for earnings

Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

The drugmaker posted adjusted earnings of 77 cents per share and now expects full-year revenue of $60.5 billion to $62.5 billion